AstraZeneca will build its first manufacturing plant in Singapore for 1,385 million

May 31. () –

AstraZeneca will build a production plant for antibody conjugates (ADC) worth 1,500 million dollars (1,385.75 million euros) in Singapore, as announced this Friday by the British laboratory, which plans to begin the design and construction of the infrastructure at the end of this year with the aim of it being operational from 2029.

The company has highlighted that with this plant it will improve the global supply of its ADC portfolio, while stating that these new generation treatments deliver anti-cancer drugs directly to cancer cells through a targeted antibody.

The plant, which is supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first comprehensive ADC production centre, incorporating all steps of the manufacturing process on a commercial scale.

ADC manufacturing, as explained by AstraZeneca, involves the production of antibodies, the synthesis of the chemotherapy drug and its linker, the conjugation of the drug linker with the antibody and the filling of the finished ADC substance.

EDB Chairman Png Cheong Boon has expressed enthusiasm for AstraZeneca’s decision to establish a manufacturing plant in Singapore for the first time as it creates “significant” jobs and economic opportunities for the country.

“I am excited that AstraZeneca will locate the $1.5 billion ADC manufacturing facility in Singapore, as it is one of the most attractive countries in the world for investment given its excellent reputation in complex manufacturing,” said the CEO. from AstraZeneca, Pascal Soriot.

For her part, the director of Oncology at AstraZeneca Spain, Laura Colón, has pointed out that the construction of this new plant is a “milestone” for AstraZeneca and a clear example of the company’s commitment to accelerate the development and production of innovative treatments. and precision that allow medical oncologists to have a greater range of possibilities to treat patients in a personalized way.

AstraZeneca, which has a broad portfolio of its own ADCs – including 6 in the clinical phase and others in preclinical development – has announced that, as part of its commitment to promoting sustainability in healthcare, it will work with the Government of Singapore and other partners in sustainable solutions for the ADC plant.